Kornimate/medical-research-clean huggingface dataset:
novel shoe device nushu to measure gait analysis in parkinson's patients

Conditions: Parkinson&#39;s Disease (PD)

Summary: gait changes in parkinson's disease are complex, variable, and difficult to detect during short clinic assessments. the aim of this study is to collect gait measurements in parkinson's patients through sensors in a novel shoe device, nushu by magnes ag. the shoe additionally provides vibrational feedback that can potentially help gait difficulties experienced by parkinson's patients.


Eligibility criteria:
parkinson's disease: inclusion criteria: 1. male or female ≥ 18 years of age. 2. a diagnosis of parkinson's disease 3. able to give written informed consent (as determined by the investigator) 4. can converse in english and read and perform all study activities 5. has willingness and ability to comply with study requirements exclusion criteria: 1. diagnosis of an atypical parkinsonism syndrome, drug-induced parkinsonism, essential tremor, or other diagnoses that explain movement symptoms other than pd 2. a diagnosis of significant cns disease other than pd such as stroke, multiple sclerosis, epilepsy 3. persons with disorders other than pd significantly affecting gait as determined by the investigator 4. history of mri brain scan indicative of clinically significant abnormality as determined by the investigator 5. inability to wear interventional device 6. unable to ambulate independently at least with assistive walking device but without additional person assistance 7. pregnant or planning pregnancy within study timeframe 8. montreal cognitive assessment (moca) score \< 22 at screening 9. resides in a nursing home or assisted care facility healthy controls: inclusion criteria: 1. male or female ≥ 18 years of age. 2. no neurological disease or other significant gait impairment as deemed by the study investigator
effects of high protein intake with intense exercise and energy deficit

Conditions: Overweight

Summary: a four week intervention will take place with the participants. they will undergo 6 days a week of high intensity training. they will also be at a 40% energy deficiency. one group will have a normal intake of protein, 1.2g/kg, while the other will have 2.4g/kg. it is our thesis that the participants with the higher protein will retain more lean mass.


Eligibility criteria:
inclusion criteria: * 18-30 males * healthy exclusion criteria: * more than 15% body fat * 35-50ml/kg/min vo2 * bmi grater than 27

Keywords: muscle protein diet exercise
efficacy evaluation of chang geng healthy drink on patients with non-alcoholic fatty liver disease

Conditions: Non-Alcoholic Fatty Liver Disease

Summary: for non-alcoholic fatty liver disease, there is currently no effective treatment options. traditional chinese medicine (tcm) has a long history of treating liver diseases. however, tcm treatment methods are diverse, and there is currently a lack of high-quality clinical research to confirm the efficacy of chinese herbal medicine. thereafter, chang-gung healthy drink which is a tcm based healthy drink may be used to alleviate the clinical adverse event of non-alcoholic fatty liver disease patients.

for non-alcoholic fatty liver disease, there is currently no effective treatment method. some studies suggest that a low-calorie diet, exercise, weight loss, etc., may help alleviate clinical symptoms, but the evidence is inconsistent. traditional chinese medicine (tcm) has a long history of treating liver diseases, and the formation of non-alcoholic fatty liver disease may be due to liver depression and blood stasis caused by spleen-stomach disharmony. in treatment, traditional chinese medicine usually focuses on soothing the liver, promoting qi circulation, activating blood circulation, and resolving blood stasis. however, tcm treatment methods are diverse, and there is currently a lack of high-quality clinical research to confirm the efficacy of chinese herbal medicine. thereafter, chang-gung healthy drink which is a tcm based healthy drink may be used to alleviate the clinical adverse event of non-alcoholic fatty liver disease patients.

Eligibility criteria:
inclusion criteria: * male and female participants aged between 20 and 75 years old. * capable of understanding and signing the informed consent form (icf) document. * diagnosed by a physician with non-alcoholic moderate fatty liver. * liver function index, ast or alt, elevated to 2 to 5 times the normal value for more than 1 month. exclusion criteria: * diagnosed with alcoholic fatty liver, viral hepatitis, autoimmune hepatitis, wilson's disease, drug-induced hepatitis, or hemochromatosis. * currently suffering from major illnesses such as cancer, stroke, end-stage kidney disease, cirrhosis. * men who consume more than 140g of alcohol per week, or women who consume more than 70g of alcohol per week. * consuming other chinese herbal medicine. * pregnant or lactating women. * patients using lipid-lowering and diabetes medications. * patients with covid-19.

Keywords: traditional chinese medicine brief fatigue inventory - taiwanese form fibroscan
one dose versus three weekly doses of benzathine penicillin g for patients with early syphilis

Conditions: Syphilis

Summary: the purpose of this study is to observe the serological response to 1 or 3 weekly doses of benzathine penicillin g in patients with early syphilis.


Eligibility criteria:
inclusion criteria: 1. persons with confirmed early symptomatic syphilis (primary or secondary) or high-titer latent syphilis 2. a rapid plasma reagin (rpr) test was positive, with a titer were 1:4 or higher. in addition, treponema pallidum particle agglutination assay and/or fluorescent treponemal antibody absorption test were reactive. exclusion criteria: 1.patients who were pregnancy, known allergy to penicillin, use of antibiotics active against syphilis during the preceding six months for symptomatic cases or during the preceding two years for asymptomatic cases, and concurrent illnesses requiring treatment with antibiotics effective against syphilis. 2. if rpr titers were found to be 1:4 or less or the t. pallidum particle agglutination test was nonreactive, participants were retrospectively excluded from the trial unless primary syphilis was confirmed by the finding of t. pallidum in ulcer exudates on direct immunofluorescence -
me-344 and bevacizumab in previously treated metastatic colorectal cancer

Conditions: Colorectal Cancer

Summary: this is a phase 1b open-label, multiple dose/schedule sequential study to determine the safety and efficacy of the oxidative phosphorylation (oxphos) pathway inhibitor me-344 in combination with bevacizumab in subjects with recurrent mcrc.

this is a phase 1b open-label, multiple dose/schedule sequential study to determine the safety and efficacy of the oxidative phosphorylation (oxphos) pathway inhibitor me-344 in combination with bevacizumab in subjects with recurrent mcrc. this study will enroll subjects with metastatic crc, including but not limited to subjects with ras wild-type or mutant tumors, msi-h/pmmr, and braf v600e, who have progressed or demonstrated intolerability to standard approved therapies which include fluoropyrimidine, oxaliplatin, irinotecan-based chemotherapies, cetuximab/panitumumab, pd-1 inhibitors, or braf inhibitors (if clinically indicated), and/or other checkpoint inhibitors. approximately 40 subjects will be enrolled in the study, in 2 cohorts of 20 subjects each. subjects will continue treatment with me-344 and bevacizumab until radiological progressive disease, unacceptable aes, withdrawal of consent, start of new anticancer therapy, or death.

Eligibility criteria:
inclusion criteria: * age ≥18 years * histological or cytological documentation of adenocarcinoma of the colon or rectum that is metastatic (all other histological types are excluded) * subjects who progressed or demonstrated intolerability to prior standard approved therapies which include fluoropyrimidine, oxaliplatin, and irinotecan-based chemotherapies, cetuximab/panitumumab (if clinically indicated e.g., ras wild-type tumors) pd-1 or braf inhibitors (if clinically indicated), and/or other checkpoint inhibitors in the metastatic setting. * previous treatment with any investigational drug or anticancer treatment must be completed \>28 days or 5 half-lives, whichever is longer, before the first dose of study treatment. * adequate bone marrow, liver, and renal function exclusion criteria: * untreated brain metastases, spinal cord compression, or primary brain tumor * symptomatic brain metastases, leptomeningeal disease, spinal cord compression, or primary brain tumor * evidence of uncontrolled or unstable cardiovascular disease, myocardial infarction (within 6 months), unstable angina pectoris, congestive heart failure, serious arrhythmias requiring drug therapy * history of cns disease * bevacizumab or aflibercept therapy ≤ 3 weeks prior to starting study treatment * peripheral neuropathy grade ≥ 2 * uncontrolled hypertension or diabetes mellitus, active peptic ulcers, unhealed wounds, clinically significant disease or systemic infections * known seropositive for, or active infection with hepatitis b or c virus * symptomatic or uncontrolled infection with human t-cell leukemia virus * venous thromboembolism (unless appropriately treated and stable on anticoagulant for at least 2 weeks).
reasons for non-treatment of hepatitis c in hcv mono-infected patients versus hcv-hiv co-infected patients in a university setting

Conditions: HIV Infections

Summary: the specific aims of this study are to determine the treatment prescription rates for hepatitis c virus (hcv) infection in a cohort of hcv mono-infected, and human immunodeficiency virus (hiv)-hcv co-infected patients and to identify the reasons for non-treatment of hcv in these two groups.

despite recent advances in treatment modalities, a large proportion of patients with hcv do not receive treatment. the reasons for non-treatment need to be elucidated to properly address these factors. appropriate evaluation and treatment of hcv is important in providing the optimal care to these persons. it is also important to document and characterize treatment patterns and prescription rates for policy, resource allocation and funding purposes. this study will determine the rates of treatment for hcv monoinfected and hcv-hiv co-infected patients, and determine the reasons for non-treatment. it will also directly compare the two populations to determine if any differences exist in the reasons for non-treatment. this study has implications for patient care, their health outcomes, policy making, funding and resource allocation.

Eligibility criteria:
inclusion criteria: * patients will be recruited from the pittsburgh aids center for treatment (pact) clinic and pitt treatment and evaluation unit (pteu) and the center for liver diseases (cld) at the university of pittsburgh. there are approximately 800 patients in the university of pittsburgh's pact/pteu clinic. consecutive patients with hcv-hiv co-infection who present to the clinic upon initiation of data gathering would be eligible for participation in this study. an estimated 500-800 patients are seen at the cld clinic per year, and consecutive patients enrolled in the cld hcv registry would be considered eligible for this study. to maintain uniformity and consistency of data, only patients seen by one of the study investigators would be enrolled. recruitment would continue till the study has enrolled 100 hcv-hiv coinfected and 200 hcv mono-infected subjects. exclusion criteria: * there are no exclusion criteria, except if the patient refuses to participate in the study.

Keywords: hiv hcv
safety and effect of intravitreal injection of a derivative of nucleoside reverse transcriptase inhibitor in subjects with diabetic macular edema

Conditions: Diabetic Macular Edema

Summary: this study is designed to assess the safety and initial evidence of efficacy of the novel compound som-401 (k8), a derivative of a nucleoside reverse transcriptase inhibitor, in subjects with untreated, clinically significant, diabetic macular edema (dme).


Eligibility criteria:
inclusion criteria: * 18 years or older * bcva of ≥ 24 and ≤ 73 letters (20/40 or worse but at least 20/320) by an etdrs chart. bcva of the non-study eye must be no worse than 20/400) * diagnosis of diabetes mellitus, type 1 or 2 with non-proliferative or non-high risk proliferative diabetic retinopathy. * dme based on investigator's clinical evaluation and demonstrated on fundus photographs, fluorescein angiograms, and spectral domain-optical coherence tomography (sd-oct) * mean foveal thickness of at least 300 µm by sd-oct * ability and willingness to comply with the treatment and follow-up procedures * ability to understand and sign the informed consent form * intraocular pressure of ≤ 21 on 2 or less iop lowering medications exclusion criteria: * pregnant patients, currently lactating patients, or females of childbearing potential (unless using reliable contraception such as double barrier, surgical sterilization, oral contraceptives, intrauterine device (iud), etc.) * allergy or hypersensitivity (known or suspected) to fluorescein or any component of the investigational product or delivery system * any ocular surgery in the study eye within 12 weeks of screening * any history of vitrectomy in the study eye * aphakia in the study eye * presence of severe foveal ischemia, defined as foveal avascular zone (faz) of \>1.5 mm2 on oct-angiography * prior intraocular or periocular treatment for dme * macular laser for the treatment of diabetic macular edema within 12 weeks of screening * any change in systemic steroidal therapy within 3 months of screening * retinal or choroidal neovascularization due to ocular conditions other than diabetic retinopathy * history or presence of viral disease of the cornea or conjunctiva * history or presence of any disease or condition that in the investigator's opinion would preclude study treatment or follow-up or that in the opinion of the investigator would render them as unlikely to benefit from study treatment. * any lens or corneal opacity which impairs visualization of the posterior pole * participation in another clinical trial within 12 weeks before the screening visit or during the study * expectation that subject will be moving away from the area of the clinical treatment center without the ability to return for visits within the study period

Keywords: diabetes kamuvudine k8 som-401
treatment of acne scars with erbium:yttrium aluminum garnet (er:yag) laser examined under oct

Conditions: Acne Vulgaris

Summary: this study is examining the effects of the 2940 nm er:yag on atrophic facial acne scars under optical coherence tomography in terms of blood flow, vessel shape, skin roughness, collagen content, and epidermal thickness.


Eligibility criteria:
inclusion criteria: 1. patients should be 18-90 years of age 2. patients should have fitzpatrick skin types of i-iii 3. patients should have at least mild acne exclusion criteria: 1. the patient should not be receiving any additional systemic, topical, or intralesional treatment of the scars during the study 2. pregnant or lactating females 3. fitzpatrick skin type of iv-vi 4. a history of keloids or hypertrophic scars 5. scleroderma 6. photosensitivity 7. botulinum toxin injection, facial laser resurfacing, chemical peels, fillers, or usage of oral retinoid within the last 6 months 8. subjects with a known history of herpes simplex

Keywords: laser er:yag laser acne acne vulgaris optical coherence tomography
cirse registry for sir-spheres therapy

Conditions: Liver Carcinoma

Summary: the administration of sir-spheres microspheres (yttrium-90 resin microspheres) is a form of selective internal radiation therapy (sirt) for the treatment of patients with primary and secondary liver tumours. the primary objective is to observe the real-life clinical application of radioembolisation with sir-spheres and the impact of the treatment in clinical practice. secondary objectives are to observe safety and effectiveness of sir-spheres treatment in terms of adverse events, overall survival (os), progression-free survival (pfs), technical considerations, liver pfs and quality of life (qol) + subgroup analyses

selective internal radiation therapy (sirt), also called radioembolisation (re), with sir-spheres microspheres is an endovascular procedure, included within the interventional oncologic technologies to treat primary and secondary liver tumours. using a microcatheter, a precise dose of resin microspheres is released in the hepatic artery, where they are carried into the arterioles and selectively lodge in the tumour microvasculature. the microspheres are loaded with the radioactive yttrium-90, a high-energy beta-emitting isotope with a half-life of 64.1 hours. following administration, 94% of the radiation is delivered in 11 days. previous reports on the safety and efficacy of yttrium-90 resin microspheres for the treatment of primary and secondary liver tumours are very promising. in order to further improve the understanding of this therapy in its true clinical setting, the cardiovascular and interventional radiological society of europe (cirse) initiated the cirse registry for sir-spheres therapy (cirt), a phase 4 observational study that aims to collect robust data on the real-life clinical practice of radioembolisation with sir-spheres microspheres. further, using the quality of life questionnaire qlq-c30 with its hepatocellular carcinoma module (developed and verified by the european organisation of research and treatment of cancer (eortc)), cirt aims to collect data on the quality of life of patients treated with sir-spheres microspheres.

Eligibility criteria:
inclusion criteria: * treatment of liver tumour with sir-spheres microspheres * primary or secondary liver tumours * signed informed consent form * 18 years or older exclusion criteria * under 18 years

Keywords: sirt microcatheter primary liver tumor secondary liver tumor radioembolisation qlq-c30 cirse
safety and efficacy clinical study of severe hemophilia b treatment with kl001

Conditions: Hemophilia B Without Inhibitor

Summary: this is an open- label, non- randomized, uncontrolled, dose-escalation pilot study to evaluate the safety and efficacy of kl001 injection solution in hemophilia b subjects with ≤2 iu/dl residual fix levels.

this is an open- label, non- randomized, uncontrolled, dose-escalation pilot study to evaluate the safety and efficacy of kl001 injection solution in hemophilia b subjects with ≤2 iu/dl residual fix levels. nine subjects will be enrolled and administered with three different doses of kl001. subjects will provide informed consent and then undergo screening assessments up to 1 month prior administration of kl001. all subjects will undergo 52 weeks safety observation and will be encouraged to enroll in an extension study to evaluate long- term safety of kl001 for a total 5 years.

Eligibility criteria:
inclusion criteria: 1. male ≥12 years of age. 2. moderate/severe or severe hemophilia b (baseline fix activity ≤2% of normal or documented history of fix activity ≤2%). 3. at least 3 bleeding episodes per year that require on-demand treatment with fix or are treated with a prophylactic regimen of fix. 4. at least 100 days exposure history to recombinant or plasma-derived fix protein products. 5. no neutralizing antibodies to exogenous fix protein products. 6. willing and able to comply with study procedures and requirements. exclusion criteria: 1. suffering from chronic inflammatory muscle disease. 2. positive in hepatitis b or hepatitis c. 3. infection with hiv-1 or hiv-2 and cd4+t cell count ≤ 200/ μ l. 4. history of thrombosis or susceptibility to thrombosis. 5. current or previous participation in another gene therapy study. 6. has any other significant medical condition that the investigator feels would be a risk to the subject or would impede the study.
complementary interventions on patients with dementia: comparative and longitudinal research

Conditions: Dementia

Summary: cognitive function, behavioral and psychological symptoms, and quality of life will improve after administration of cognitive stimulation therapy, reminiscence therapy, and aroma-massage therapy in patients with dementia.

this study will base on the pattern of behavioral and psychological symptoms of dementia, to verify and compare the effectiveness of the three non-pharmacological complementary interventions, cognitive stimulation therapy, reminiscence therapy, and aroma-massage therapy on patients' cognitive function, behavior and psychological symptoms, and quality of life.

Eligibility criteria:
inclusion criteria: * been diagnosed with dementia (all stages) or mmse below 23 for high school educated and 17 for less than high school education * able to communicate verbally or nonverbally * able to understand short sentences * can sit for at least 50 mins. exclusion criteria: * no hospitalization within the past two weeks * not under severe acute illness * no psychiatric disorders.

Keywords: dementia behavioral and psychological symptoms quality of life
assessment of a follow-up with tele-consulting for patients with renal failure under peritoneal dialysis

Conditions: Chronic Renal Failure; Peritoneal Dialysis

Summary: the objective of the study is to determine whether tele-consulting for the follow up of patients with renal failure under peritoneal dialysis would not increase the risk of experiencing a severe adverse event


Eligibility criteria:
inclusion criteria: * patient under peritoneal dialysis for more than three month * patient thought to be able to perform peritoneal dialysis alone or with the help of health care professionnals * patients or health care professionnals thought to be able to use telemedicine exclusion criteria: * no dsl network * no gsm network * patients who can not express their opposition to the participation to this study because of limited mental abilities
drug burden index is associated with malnutrition in community-dwelling dementia patients

Conditions: Malnutrition Severe; Dementia; Drug Use; Anticholinergic Toxicity

Summary: malnutrition leads to poor clinical outcomes in dementia patients. the investigator aimed to examine the association between drug burden index (dbi) and anticholinergic burden (acb) scores with nutrition status in community-dwelling older adults with dementia, considering that drugs may contribute malnutrition. a total of 415 outpatients with dementia, evaluated by mini nutrition assessment test and registered drug information, are included in the study. the investigator calculated the dbi as the sum of all sedatives and anticholinergics taken continuously for at least four weeks prior to admission and evaluated the acb score. practice impact: due to accompanying chronic diseases and symptoms, cholinergic and/or sedative-loaded drugs are often prescribed to dementia patients. in this study, i̇nvestigators emphasized that in addition to the cholinergic loads of the drugs used, their sedative loads and the drug doses they use are also important. avoiding prescribing these medications to patients with dementia will protect them from malnutrition and its negative consequences.


Eligibility criteria:
inclusion criteria: * clinical diagnosis of any type of demantia * must be able to swallow tablets * must be recorded data of medications and doses exclusion criteria: * psychiatric disorders * mild cognitive impairment * end-stage diseases (renal, liver, cardiac) * uncontrolled thyroid functions

Keywords: drug burden index, older adults malnutrition anticholinergic drugs dementia